Literature DB >> 9626228

Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma.

J E Gershenwald1, M I Colome, J E Lee, P F Mansfield, C Tseng, J J Lee, C M Balch, M I Ross.   

Abstract

PURPOSE: To determine the patterns of recurrence and causes of regional nodal basin failure in stage I or II melanoma patients who had a histologically negative sentinel lymph node (SLN) and whose regional nodal basins were not dissected following lymphatic mapping and SLN biopsy. PATIENTS AND METHODS: The records of 344 patients with primary cutaneous melanoma who underwent lymphatic mapping and SLN biopsy between 1991 and 1995 at The University of Texas M.D. Anderson Cancer Center were reviewed. Of 322 patients who underwent successful lymphatic mapping procedures, 270 had histologically negative SLNs; mapped nodal basins were observed without further surgical intervention in 243 of these 270 patients. Recurrence patterns were analyzed from this cohort and a histologic reevaluation of all previously identified SLNs on which a biopsy had been taken was performed in patients who developed recurrent disease.
RESULTS: Of 243 patients with a histologically negative SLN, 27 (11%) developed local, in-transit, regional nodal, and/or distant metastases after a median follow-up time of 35 months. Ten patients (4.1%) developed a nodal recurrence in the previously mapped basin, either solely or as a component of the first site of recurrence. Detailed analysis of the SLNs in these 10 patients demonstrated evidence of occult metastases in 80% by serial sectioning or immunohistochemical staining.
CONCLUSION: Regional nodal failures in melanoma patients following a negative SLN biopsy are infrequent and to date have most commonly occurred because conventional histologic evaluation was unable to identify occult metastatic disease. These data provide further evidence that lymphatic mapping and SLN biopsy accurately reflect the status of the regional nodal basin. Specialized pathologic techniques are necessary to reduce further the already low false-negative rates and to improve disease staging.

Entities:  

Mesh:

Year:  1998        PMID: 9626228     DOI: 10.1200/JCO.1998.16.6.2253

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  67 in total

1.  Credentialing for breast lymphatic mapping: how many cases are enough?

Authors:  H S Cody; A D Hill; K N Tran; M F Brennan; P I Borgen
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

2.  The argument against sentinel node biopsy for malignant melanoma.

Authors:  J M Thomas; E J Patocskai
Journal:  BMJ       Date:  2000-07-01

Review 3.  A review of sentinel lymph node biopsy for thin melanoma.

Authors:  K M Joyce; N M McInerney; C W Joyce; D M Jones; A J Hussey; P Donnellan; M J Kerin; J L Kelly; P J Regan
Journal:  Ir J Med Sci       Date:  2014-11-01       Impact factor: 1.568

4.  Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness <1.00 mm) on the basis of a long-term follow-up.

Authors:  Torsten Hinz; Hojjat Ahmadzadehfar; Anja Wierzbicki; Tobias Höller; Jörg Wenzel; Hans-Jürgen Biersack; Thomas Bieber; Monika-H Schmid-Wendtner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-08       Impact factor: 9.236

Review 5.  Role of sentinel node biopsy in the management and staging of the N0 neck.

Authors:  Gary L Ross; Taimur Shoaib
Journal:  Odontology       Date:  2005-09       Impact factor: 2.634

6.  Sentinel lymph node biopsies in cancers of the skin, colon, head and neck, and breast.

Authors:  Bridget M Nelson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-04

Review 7.  Clinical and biological aspects of sentinel node biopsy in malignant melanoma--an update.

Authors:  Isabel Callejo Peixoto; José Meneses e Sousa
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

Review 8.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

9.  Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

Authors:  Emily Z Keung; Jeffrey E Gershenwald
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

10.  Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result.

Authors:  Edward L Jones; Teresa S Jones; Nathan W Pearlman; Dexiang Gao; Robert Stovall; Csaba Gajdos; Nicole Kounalakis; Rene Gonzalez; Karl D Lewis; William A Robinson; Martin D McCarter
Journal:  JAMA Surg       Date:  2013-05       Impact factor: 14.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.